News
-
-
PRESS RELEASE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387 -
-
PRESS RELEASE
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections -
-
PRESS RELEASE
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides, Inc. reports investigating NV-387 for MPOX treatment under WHO MEURI protocol amidst 2024 outbreak. NV-387 shows promise in animal studies for broad-spectrum antiviral use -
-
PRESS RELEASE
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected -
-
PRESS RELEASE
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides provides update on clinical program & strategy for novel antiviral drug NV-387, targeting Influenza, COVID, RSV & more. Broad-spectrum potential discussed
